Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Biochimica Et Biophysica Acta|June 10, 2009
HCV-NS3 inhibitors: determination of their kinetic parameters and mechanismMaría Victoria Flores, Joanne Strawbridge, Giuseppe Ciaramella, et al.Journal of Virology|December 13, 2002
Regulation of minute virus of mice NS1 replicative functions by atypical PKClambda in vivoJürg P F Nüesch, Sylvie Lachmann, Romuald Corbau, et al.Annals of Neurology|October 1, 2016
RNAi prevents and reverses phenotypes induced by mutant human ataxin-1Megan S Keiser, Alejandro Mas Monteys, Romuald Corbau, et al.Bioorganic & Medicinal Chemistry Letters|August 28, 2009
Pyrazole NNRTIs 1: design and initial optimisation of a novel templateCharles E Mowbray, Catherine Burt, Romuald Corbau, et al.Journal of Virology|June 1, 2007
Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virusDimitri Lavillette, Eve-Isabelle Pécheur, Peggy Donot, et al.European Journal of Medicinal Chemistry|April 10, 2013
Identification of novel FLT3 kinase inhibitorsDaphnie Pauwels, Hugo Klaassen, Idoya Lahortiga, et al.Chemical Biology & Drug Design|March 1, 2011
Comparison of the non-nucleoside reverse transcriptase inhibitor lersivirine with its pyrazole and imidazole isomersLyn H Jones, Gill Allan, Romuald Corbau, et al.Bioorganic & Medicinal Chemistry Letters|September 1, 2009
Pyrazole NNRTIs 3: optimisation of physicochemical propertiesCharles E Mowbray, Romuald Corbau, Michael Hawes, et al.Chemmedchem|October 16, 2008
Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitorsLyn H Jones, Gill Allan, Romuald Corbau, et al.Blood Advances|July 15, 2022
Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepanciesJonathan H Foley, Erald Shehu, Anne Riddell, et al.Pageof 2